Rounding out a very successful 2019, PetMedix is pleased to announce that our R&D capabilities have been strengthened with Dr Dave Lowery joining the company as Chief Product Development Officer.
Dave has 30+ years of leadership experience in the Animal Health industry, with wide-ranging R&D experience in vaccines, pharmaceuticals, parasiticides, and within that has spent the last ten years bringing modern antibody-based drugs to the Animal Health market.
It is this knowledge of antibody therapeutics and their development, particularly from a companion animal perspective, that Dave can bring to bear at PetMedix. We are fortunate that our scientific team has a great deal of experience in building the transgenic platforms and in using them for drug discovery. What Dave brings is the know-how in taking those drug candidates through canine studies, manufacturing, and eventually on to regulatory approval.
Dave’s experience spans several of the large Animal Health pharmaceutical companies, starting with The Upjohn Company, and continuing through Pharmacia, Pfizer, Novartis, Elanco, Merial, and Boehringer Ingelheim. He has always worked in the Animal Health space, but has also always been in close collaboration with human health pharmaceutical R&D.
“We were looking for an experienced product developer from animal health with a specific and rare combination of skills, and are very happy to have found that person in Dave.” Says PetMedix’s CEO, Dr Tom Weaver. “Antibodies are a relatively recent innovation for animal health, and so to have someone join us with this level of relevant experience is a great asset. I feel that it also stands testament to the quality of the science at PetMedix that we are able to attract talent like this.”
Dave received his B.S. in biochemistry from the University of Illinois, and a Ph.D. in biochemistry from University of Illinois. He has authored 60+ papers in various areas of animal health, and is inventor on 10+ patents. He also has a wide knowledge of Animal Health markets and opportunities.
